21 September 2022 | Other

Merck to begin testing lower dose HIV drug after FDA approval

Merck & Co Inc. has announced a start of last-stage trials for its HIV drug, known as islatravir. The event comes months after the U.S. Food and Drug Administration (FDA) suspended the study, citing safety issues.

As the company states, the Health Department agency reconsidered the plan, agreeing to lower the dose of the once-a-day pills to treat patients with HIV.

Back in December 2021, the FDA completely shelved six studies aimed at developing HIV therapies. Concurrently, the regulator suspended 7 projects, noting some patients were experiencing a lower level of immune system cells that help combat infections.

Merck reported resuming clinical trials of isletravir at lower doses, particularly for adults with HIV-1.

Several higher-dose projects using isletravir are also under clinical hold.

Company MarketCheese
Period: 25.07.2025 Expectation: 440 pips
AUDCAD gains on technical bounce and improved sentiment in commodity markets
Today at 10:05 AM 28
Period: 25.07.2025 Expectation: 1700 pips
GBPUSD struggles to regain momentum as uptrend breaks
Today at 09:14 AM 26
Period: 25.07.2025 Expectation: 222 pips
Buying natural gas with target at 3.780 amid record heatwaves in US and Asia
Yesterday at 10:49 AM 62
Period: 25.07.2025 Expectation: 15000 pips
ETHUSD rally accelerates as US moves forward with crypto legislation
Yesterday at 10:13 AM 65
Period: 23.07.2025 Expectation: 600 pips
USDCAD gains strength amid dollar rally and falling oil prices
16 July 2025 86
Period: 25.07.2025 Expectation: 1000 pips
Nvidia's return to China pushes shares toward 180 level
16 July 2025 78
Go to forecasts